Phase I, Open-label, Single Sequence, Two-Period Study to Evaluate the Effect of Tepotinib on P-gp by Investigating the PK of the P-gp Probe Substrate Dabigatran Etexilate in Healthy Subjects
Latest Information Update: 09 Aug 2023
At a glance
- Drugs Tepotinib (Primary) ; Dabigatran etexilate
- Indications Liver cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 03 Aug 2023 Interventional Study Model changed to Crossover, Number of treatment arms changed to 2.
- 10 Sep 2018 Status changed from recruiting to completed.
- 16 Jul 2018 Planned End Date changed from 20 Jul 2018 to 6 Aug 2018.